Subscribe to Email Alerts
Menu
About Us
About INOVIQ
Market Opportunity
Board
Management
Medical & Scientific Advisory Board
Partners
Distributors
Compliance
Careers
Technology
Our Science
NETs Platform
SubB2M Platform
BARD1 Biomarker Technology
hTERT ICC Assay
Intellectual Property
Publications
Resources
Business Development
Products
Our Products
EXO-NET® Pan-Exosome
Product Overview
Technical Information
Data & Figures
Ordering
hTERT ICC Test
Pipeline
Development Pipeline
NeuCA15-3 Test
NeuCA125 Test
EXO-Ovarian Cancer Test
Exosome Therapeutics
Investors
Investor Overview
ASX Announcements
Annual & Financial Reports
Presentations
Share Price Information
AGM
INOVIQ Fact Sheet
Corporate Governance
Shareholder Services
FAQ
Analyst Reports
News & Events
INOVIQ in the News
Conferences & Events
Contact
Contact Us
Subscribe to Email Alerts
ASX Announcements
Heading &
Sub-heading can be edited through HQI
Investors
>
ASX Announcements
Investor Overview
ASX Announcements
Annual & Financial Reports
Presentations
Share Price Information
AGM
INOVIQ Fact Sheet
Corporate Governance
Shareholder Services
FAQ
Analyst Reports
ASX Announcements
Filter by Year:
2025
2024
2023
2022
2021
2020
2019
16-May-2022
Change of Director's Interest - Philip Powell
10-May-2022
IIQ Investor Presentation
9-May-2022
Change of Director's Interest - Dr Geoffrey Cumming
4-May-2022
Change of Director's Interest - Philip Powell
3-May-2022
INOVIQ Investor Briefing Invitation
3-May-2022
Australian Patent Granted for SubB2M Technology
2-May-2022
INOVIQ Key Manufacturing Agreement to Advance SubB2M tests
29-Apr-2022
IIQ Appendix 4C & Quarterly Activities Report - March 2022
26-Apr-2022
INOVIQ CSO Co-Authors Scientific Statement on Exosomes
21-Apr-2022
Notification of cessation of securities - IIQ
Previous
1
2
3
4
5
6
Next